Particular aspects of platinum compounds used at present in cancer treatment
| Autor: | Claudie Madoulet, Bernard Desoize |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
endocrine system diseases
medicine.medical_treatment Drug Resistance Antineoplastic Agents Platinum Compounds Pharmacology chemistry.chemical_compound Pharmacokinetics Neoplasms Animals Humans Medicine Nedaplatin Cisplatin Cervical cancer Chemotherapy Molecular Structure business.industry Hematology medicine.disease Carboplatin Cancer treatment Oxaliplatin Oncology chemistry Cancer research business medicine.drug |
| Zdroj: | Critical Reviews in Oncology/Hematology. 42:317-325 |
| ISSN: | 1040-8428 |
| DOI: | 10.1016/s1040-8428(01)00219-0 |
| Popis: | The history of platinum in cancer treatment began 150 years ago with the first synthesis of cisplatin; but it was not used in the clinic before 30 years ago. Then 3000 derivatives were synthesised and tested, with poor successes: three other derivatives only are available today. Clearly they are not more active, but they are less toxic than cisplatin, although two, carboplatin and nedaplatin, yield a cross-resistance, while one, oxaliplatin, does not. Their mechanisms of action are similar: these four pro-drugs form adducts with DNA, impairing DNA synthesis and repair then. Their pharmacokinetics are complicated since we always measure two overlapping pharmacokinetics: those of the parent compound and of the bound platinum. Cisplatin is now recommended for few cancers, it is replaced by less-toxic carboplatin, and therefore more easily used in combination. Oxaliplatin give interesting results in a number of cancers. The official recommendation in Japan for nedaplatin is head and neck, testicular, lung, oesophageal, ovarian, and cervical cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect